Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting.
The U.S. Supreme Court on June 1, 2023, unanimously settled a pivotal dispute over the subjective versus objective standard for scienter under the False Claims Act (FCA). In this case, U.S. ex rel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results